聪明文档网

聪明文档网

最新最全的文档下载
当前位置: 首页> 正在进行安全检测...

正在进行安全检测...

时间:2023-11-17 13:57:15    下载该word文档
心电与循环2019年第38卷第4Endo-PAT评估剂量叶酸冠心病者血管功能影响林辉翟小蒋承建孟立平郭艳池菊芳郭航远[摘要]目的探讨无创血管功能系统Endo-PAT评估剂量叶酸对冠心病功能影响方法冠心病104为叶酸低剂量n=36叶酸剂量n=33和对n=35给予冠心病常疗,叶酸低剂量叶酸剂量上述基础上别给予5mg15mg叶酸疗,访6个月测定水平Hcy水平和血志物应性RHI动脉内膜中厚度IMTPeasrson相关分析RHIIMT相关性。结果6个月疗后3低密度脂蛋白胆固醇LDL-C胆固醇TC甘油三酯TGHcy水平1ET-1细胞间黏附分子1sICAM-1下降度脂蛋白胆固醇HDL-C和一氧化氮NOP0.05叶酸剂量组与叶酸低剂量LDL-CTCTGET-1NOsICAM-1水平比差异计学意义P0.05叶酸低剂量叶酸剂量HDL-C水平增加P0.05Hcy水平叶酸剂量叶酸低剂量疗后,3RHIIMT下降叶酸低剂量和高剂量下降大于P0.05叶酸剂量组与叶酸低剂量RHIIMT差异无计学意义P0.05相关分析叶酸低剂量和高剂量RHI增加IMT相关r=-0.6034-0.7381P0.01结论剂量叶酸合临床冠心病者的疗。冠心病功能Endo-PAT叶酸氨酸[关键词]TheeffectsofdifferentdosageoffolicacidonvascularendothelialfunctioninpatientswithcoronaryheartdiseasebyEndo-PATLINHui,ZHAIXiaoya,JIANGChengjian,etal.DepartmentofCardiology,ShaoxingPeoplesHospitalShaoxingHospital,ZhejiangUniversitySchoolofMedicine,Shaoxing312000,ChinaCorrespondingauthor:GUOHangyuan,E-mailghangyuan@hotmail.com[Abstract]ObjectiveToinvestigatetheeffectsofdifferentdosageoffolicacidonendothelialfunctioninpatientsMethods104patientswithcoronaryheartdiseaseadmittedtoourhospitalfromJanuarywithcoronaryheartdisease.2016toJanuary2018wereenrolled.Patientswererandomlyassignedtothecontrolgroupn=35,low-dosefolicacidgroupLF,n=36andhigh-dosefolicacidgroupHF,n=33.Thecontrolgroupreceivedconventionaltreatmentforcoronaryheartdisease.LFgroupandHFgroupweregiven5mgand15mgoffolicacid,respectively,inadditiontobasicconventionaltreatment.Thelevelsofbloodlipid,homocysteineHcyandendotheliummarkers,andthereactivehyperemiaindexRHIandcarotidintima-mediathicknessIMTweremeasuredbeforeandaftertreatmentof6months.PeasrsoncorrelationanalysiswasusedtoevaluatetherelationshipbetweenRHIandIMT.ResultsThelevelsoflow-densitylipoproteinLDL-C,totalcholesterolTC,triglycerideTG,plasmaHcy,endothelin-1ET-1andsolubleintercellularadhesionmolecule-1sICAM-1decreased,whilehigh-densitylipoproteinHDL-CandnitricoxideNOincreasedinall3groupsafter6months'treatmentP0.05forall.LDL-C,TC,TG,ET-1,NOandsICAM-1werenotsignificantdifferencebetweenLFandHFgroups.ComparedwithcontrolgroupandLFgroup,HDL-ClevelincreasedinHFgroupP0.05.HcywaslowerinHFgroupthanLFgroup.Aftertreatment,RHIandIMTdecreasedinall3groups,andthedecreaseofRHIandIMTinLFandHFgroupswassignificantlygreaterthanincontrolgroupP0.05.TherewasnosignificantdifferenceofRHIandIMTbetweenLFgroupandHFgroup.AnalysisshowedtherewasanegativeDOI10.12124/j.issn.2095-3933.2019.4.2019-3720计划2015B70046单位312000浙江医院浙江大学医院通信作郭航E-mailghangyuan@hotmail.com·292·
心电与循环2019年第38卷第4correlationbetweentheincreaseofRHIandthedecreaseofIMTinbothLFandHFgroupsr=-0.6034-0.7381,allP0.01.ConclusionLow-dosefolicacidissuitableforthetreatmentofpatientswithcoronaryheartdisease.[Keywords]CoronaryheartdiseaseEndothelialfunctionEndo-PATFolicacidHomocysteine血管内障碍是动粥样早期是心血管事件的始动障碍早期诊断早期血管内能,血管进行早期对于粥样的进重要临床[1]国对血管内能的认知及应用于国水平[2]同型Hcy血症心病损害重要危险[3]。研究15mg低血Hcy[5]研究中,现小5mg治疗8绞痛Hcy水平[4]。在基础究应用行的无创血管内能检测系统En-do-PAT2000心病Hcy水平能的能的Hcy报道1对象和方法1.1选取2016120181医院院并诊冠心病冠状104法分成335191645~7863.46±4.38心病治疗包括阿托10mg/d林片100mg/d氯吡雷片75mg/d根据使血管A-CEI或血管阻滞ARBβ-阻滞等。36221442~8064.59±4.85在对治疗基础5mg力生1/d33211246~7966.83±5.30在对治疗基础15mg/d每次5mg3/d3者性别并高血压、BMI均无(均P0.05研究经过,者均同意同意签署知情同意书标准:冠状性的标准为冠状影显冠状冠状1以上血管50者均行冠状标准:严重全,糖尿病,骨髓病,脑卒其他病。随访61.21.2.1能指评估。受试者在试验8h禁止咖啡运动。在安线房间PATEndo-PAT2000ItamarMedicalLtdCaesarea色列指指指动脉脉振幅。在试验血压箍带200/250mmHg1mmHg=0.133kPa线60mmHg5min箍带放诱发箍带放90~120s振幅线振幅标准的对PAT化比较,应性指数RHI和分动进行。RHI1.67示内障碍1.2.2超声检查B超声诊断完成超声检查时患45°率为7.5~10MHz超声颈部颌角脉位置舒张量颈1cm膜厚IMT3IMT1.0mm1.01.2mm为内1.2mm斑块成。1.2.3院后15ml管内30min3000r/min15min免疫吸附ELISAHcy1ET-1人可1sICAM-1和一NO水平用全蛋白胆固醇LDL-C蛋白胆固HDL-C总胆固醇TC甘油TG水平1.3处理SPSS22.0计量资料,多单因素·293·
心电与循环2019年第38卷第4两两SNK-q检验,间治疗前t检验资料验。RHIIMT性分PearsonP0.05222.1结果3心病治疗前后血水平113心病治疗前后血水平n363335LDL-Cmmol/L治疗前2.63±0.302.69±0.272.67±0.21治疗2.06±0.12*2.03±0.11*2.22±0.14*HDL-Cmmol/L治疗前1.03±0.131.02±0.091.07±0.14治疗1.27±0.16*1.39±0.20*△▲1.18±0.18*TCmmol/L治疗前4.74±0.574.62±0.534.67±0.64治疗3.51±0.36*3.47±0.34*3.79±0.31*TGmmol/L治疗前2.17±0.292.16±0.412.20±0.34治疗1.20±0.22*1.24±0.19*1.42±0.18**治疗前较,P0.05较,P0.05较,P0.051可见治疗前较,3治疗LDL-CTCTG水平HDL-C水平均有P0.05较,治疗LDL-CTCTG水平(均P0.05LDL-CTCTG水平均无(均P0.05较,HDL-C水平P0.052.23心病治疗前后血Hcy血管内223心病治疗前后血Hcy血管内nHcymol/L治疗前治疗ET-1pg/ml治疗前88.47±8.7390.01±10.7386.72±11.49治疗NOmol/L治疗前治疗sICAM-1g/L治疗前治疗219.47±10.75*115.49±13.62*231.73±12.49*3615.97±3.188.71±1.69*3316.19±3.327.02±1.75*△▲3516.25±3.1610.72±2.55*60.63±9.58*48.96±7.9768.63±9.66*273.96±16.0857.53±8.68*50.74±9.4270.50±8.05*269.82±15.5367.28±9.61*50.23±7.5361.27±8.24*270.47±11.38*治疗前较,P0.05较,P0.05较,P0.052可见治疗前相3治疗后血Hcy水平均有(均P0.05较,治疗Hcy水平(均P0.05Hcy水平P0.05ET-1sICAM-1水平明显于对NO水平于对均有(均P0.05ET-1NOsICAM-1水平较,均无P0.052.33心病治疗前后内能和333心病治疗前后内能和n363335RHI治疗前1.28±0.181.29±0.231.31±0.19治疗1.95±0.19*IMTmm治疗前1.38±0.181.39±0.361.39±0.29治疗1.10±0.15*RHI治疗前---治疗0.340.070.680.040.770.09治疗前---IMT治疗-0.14±0.09-0.25±0.13-0.30±0.162.02±0.16*1.63±0.25*1.06±0.17*1.25±0.21**治疗前较,P0.05较,P0.05ΔRHI=治疗RHI-治疗前RHIΔIMT=治疗IMT-治疗前IMT3可见治疗前较,3治疗RHI高、IMT均有(均P0.05治疗RHI较对高、IMT较对(均P0.05RHIIMTP0.05较,·294·
心电与循环2019年第38卷第4治疗前RHIIMT改变均有P0.05A0.0-0.2-0.4-0.60.51r=-0.6034P0.0001B0.0-0.2-0.4-0.60.02.4治疗前RHIIMT1r=-0.7381P0.0001C0.0-0.1-0.2-0.30.51.01.5-0.40.00.20.4ΔRHI0.60.8r=-0.2264P=0.19100.60.7ΔRHI0.80.9ΔRHI治疗前RHIIMTPearson性分ABC由图1可见RHIIMT线RHIIMTr=-0.6034-0.7381P0.013讨论血管内能是心血管危险因素中的终危血管风险因素中的一项重要立预测[6-7]。利用血管内对动粥样病的危险人严重均有重要用。Hcy血症可释放使ET-1NO水平血管粥样化加[8]用的检中,NOET-1sICAM-1等)[9]虽然治疗善冠心病管内能,Hcy血症者,确切及作[10]研究10mg能,量增40mg时并能进一能。的,研究管高15mg5mg能进一心病者,但并NOET-1sICAM-1水平能的用。护作是完全依赖Hcy水平高低大多数实验能的[11]Endo-PAT2000无创血管内诊断系统/外周PAT的一项无创便可重的定。研究En-do-PAT得出RHI血管内BMITC/HDL-C危险因素与RHI[12]Akiyama[13]321力衰竭患者行Endo-PAT障碍事件发生率4时外周血管内障碍血管事件立相于心力衰竭患风险RHI心病冠状斑块形态RHI者较RHI斑块更易[14]研究均RHI心病能检是,有研究运用RHI评估能的用,Hcy血症损害研究运用Endo-PAT系统期早期血管内能。研究较,6心病RHIIMTRHIIMTRHI效评估治疗前IMT改变先前有研究H高血压患IMT[15]的研究表明IMT斑块冠状粥样大动改变密切IMT冠状[16-17]RHI用于评估冠状严重预前后内能的改变注意阿托本身善冠心病血管内[18]研究在阿托治疗基础酸具同作用,进一心病水平19]先前研究[15进一步提量增HDL-C水平无法LDL-CTCTG水平考虑应,阿托临床治疗冠心病者。研究在一定的性。首先研究·295·
者数,无法对进行包括冠状严重等的次,由于随访无法估不治疗对心血管事件研究心病治疗基础治疗进一步提HDL-C管高Hcy但并能进一能,能的护作完全依赖Hcy治疗RHIIMTRHIIMTEndo-PAT早期评估冠心病能的无创便快速的检并可用于后内查。[1]GimbroneMA,Garcia-CardenaG.EndothelialCellDysfunctionandthePathobiologyofAtherosclerosis[J].CircRes,2016,1184620-636.DOI10.1161/CIRCRESAHA.115.306301.[2]TakayamaT,HiroT,YodaS,etal.EffectofAggressivelipid-low-eringtreatmentwithRosuvastatinonvascularendoTHeliumfunc-tion:evaluationofvascularendotheliumfunctionEARTHstudy[J].HeartVessels,2018,336590-594.DOI10.1007/s00380-017-1094-0.[3]KollerA,SzenasiA,DornyeiG,etal.CoronaryMicrovascularandCardiacDysfunctionDuetoHomocysteinePathometabolism;AComplexTherapeuticDesign[J].CurrPharmDes,2018,24252911-2920.DOI10.2174/1381612824666180625125450.[4]GuoH,ChiJ,XingY,etal.Influenceoffolicacidonplasmaho-mocysteinelevels&arterialendothelialfunctioninpatientswithunstableangina[J].IndianJMedRes,2009,1293279-284.[5]BaszczukA,ThielemannA,MusialikK,etal.TheImpactofSup-plementationwithFolicAcidonHomocysteineConcentrationandSelectedLipoproteinParametersinPatientswithPrimaryHyper-tension[J].JNutrSciVitaminolTokyo,2017,63296-103.DOI10.3177/jnsv.63.96.[6]YangO,LiJ,KongJ.TheEndotheliumasaTargetfortheTreat-mentofHeartFailure[J].CellBiochemBiophys,2015,723751-756.DOI10.1007/s12013-015-0526-7.[7]MatsuzawaY,GuddetiRR,KwonTG,etal.Secondarypreventionstrategyofcardiovasculardiseaseusingendothelialfunctiontesting[J].CircJ,2015,794685-694.DOI10.1253/circj.CJ-15-0068.[8]ChenJY,YeZX,WangXF,etal.Nitricoxidebioavailabilitydys-·296·心电与循环2019年第38卷第4functioninvolvesinatherosclerosis[J].BiomedPharmacother,2018,97,423-428.DOI10.1016/j.biopha.2017.10.122.[9]BrunoRM,GoriT,GhiadoniL.Endothelialfunctiontestingandcardiovasculardisease:focusonperipheralarterialtonometry[J].VascHealthRiskManag,2014,10577-584.DOI10.2147/VHRM.S44471[10]谢晓,张古,孙建,.比较不同剂量叶酸联合依那普利治疗H高血压心病的[J].中国民康医学,2018,30519-21.DOI10.3969/j.issn.1672-0369.2018.05.008.[11]潘孙雷,池菊芳,郭航远.叶酸脉粥样硬化干预机制研究进展[J].浙江医学,2017,39232186-2189.DOI10.12056/j.issn.1006-2785.2017.39.23.2016-1776.[12]HamburgNM,KeyesMJ,LarsonMG,etal.Cross-sectionalrela-tionsofdigitalvascularfunctiontocardiovascularriskfactorsintheFraminghamHeartStudy[J].Circulation,2008,117192467-2474.DOI10.1161/CIRCULATIONAHA.107.748574.[13]AkiyamaE,SugiyamaS,MatsuzawaY,etal.Incrementalprog-nosticsignificanceofperipheralendothelialdysfunctioninpatientswithheartfailurewithnormalleftventricularejectionfraction[J].JAmCollCardiol,2012,60181778-1786.DOI10.1016/j.jacc.2012.07.036.[14]SchoenenbergerAW,UrbanekN,BergnerM,etal.Associationsofreactivehyperemiaindexandintravascularultrasound-assessedcoronaryplaquemorphologyinpatientswithcoronaryarterydis-ease[J].AmJCardiol,2012,109121711-1716.DOI10.1016/j.amjcard.2012.02.011.[15]白艳.叶酸联合阿托伐他汀H高血压患者颈总脉内膜层厚影响[J].河北医学,2018,246955-958.DOI10.3969/j.issn.1006-6233.2018.06.019.[16]蒋鹏,姜巧珍,任鸿坤,.最大颈脉内膜层厚度及斑块对冠心病预测相关研究[J].临床心血管病杂志,2015,315532-535.DOI10.13201/j.issn.1001-1439.2015.05.017.[17]ItogaNK,TawfikDS,LeeCK,etal.AssociationofBloodPressureMeasurementsWithPeripheralArteryDiseaseEvents[J].Circula-tion,2018,138171805-1814.DOI10.1161/CIRCULA-TIONAHA.118.033348.[18]尔周,,许贤彬.不同剂量阿托伐他汀对冠心病病Rho激酶活性和功能影响[J].西结合血管病杂,2017,15222856-2858.DOI10.3969/j/issn.1672-1349.2017.22.017.[19]李玲.阿托伐他汀联合来酸依那普利叶酸片治疗H高血患者61临床研究[J].用医杂志,2018,25101141-1142.DOI10.19522/j.cnki.1671-5098.2018.10.038.收稿日期2019-05-06文编辑:雯娜

免费下载 Word文档免费下载: 正在进行安全检测...

  • 29.8

    ¥45 每天只需1.0元
    1个月 推荐
  • 9.9

    ¥15
    1天
  • 59.8

    ¥90
    3个月

选择支付方式

  • 微信付款
郑重提醒:支付后,系统自动为您完成注册

请使用微信扫码支付(元)

订单号:
支付后,系统自动为您完成注册
遇到问题请联系 在线客服

常用手机号:
用于找回密码
图片验证码:
看不清?点击更换
短信验证码:
新密码:
 
绑定后可用手机号登录
请不要关闭本页面,支付完成后请点击【支付完成】按钮
遇到问题请联系 在线客服